IP Library Granted Patent US 7,405,237
Granted Patent B2
US 7,405,237 · App. 10/900,332 · Granted Jul 29, 2008

Isoindoline compounds and methods of their use

Assignee: Celgene Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,405,237
App. No.
10/900,332
Granted
Jul 29, 2008
Kind
B2
Abstract

Novel isoindoline compounds are disclosed. Methods of treating, preventing and/or managing cancer, diseases and disorders associated with, or characterized by, undesired angiogenesis, and diseases and disorders mediated by PDE 4, using the compounds are also disclosed.

Claims (7)

1. A compound, or a pharmaceutically acceptable salt or solvate thereof, wherein the compound is:

2. A compound, or a pharmaceutically acceptable prodrug thereof, wherein the compound is:

3. A compound, or a pharmaceutically acceptable stereoisomer thereof, wherein the compound is:

4. A pharmaceutical composition comprising a compound of claim 1 , 2 , or 3 .

5. The pharmaceutical composition of claim 4 , which further comprises a second active ingredient.

6. The pharmaceutical composition of claim 5 , wherein the second active ingredient is anti-CD40 monoclonal antibody, histone deacetlyase inhibitor, heat-shock protein-90 inhibitor, insulin-like growth factor-1 receptor kinase inhibitor, vascular endothelial growth factor receptor kinase inhibitor, inducer of apoptosis in mutiple myeloma cell, statin, insulin growth factor receptor inhibitor, lysophosphatidic acid acyltransrerase inhibitor, IkB kinase inhibitor, p38MAPK inhibitor, EGFR inhibitor, HER-2 antibody, VEGFR antibody, VEGFR inhibitor, P13K inhibitor, C-Met inhibitor, monoclonal antibody, anti-TNF-α antibody, hematopoietic growth factor, cytokine, anti-cancer agent, antibiotic, cox-2 inhibitor, immunomodulatory agent, immunosuppressive agent, or corticosteroid.

7. The pharmaceutical composition of claim 5 , wherein the second active ingredient is 2-methoxyestradiol, telomestatin, gefitinib, erlotinib HCL, trastuzumab, pertuzumab, bevacizumab, wortmannin, rituximab, tositumomab, edrecolomab, semaxanib, cyclosporin, etanercept, doxycycline, bortezomib, oblimersen, melphalan, G-CSF, GM-CSF, EPO, a cox-2 inhibitor, topotecan, pentoxifylline, ciprofloxacin, taxotere, irinotecan, dexamethasone, doxorubicin, vincristine, IL 2, IFN, dacarbazine, Ara-C, vinorelbine, isotretinoin, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 4, 2019
From: CELGENE CORPORATION
To: AMGEN INC.
Reel/Frame 051181/0038 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 23, 2004
From: MULLER, GEORGE W.; MAN, HON-WAH
To: CELGENE CORPORATION
Reel/Frame 016018/0184 →
Continuity (1)
Related Publication 20060025457A1 · Feb 2, 2006